Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

SGMC Health recently achieved the successful completion of its first transcarotid access Transcatheter Aortic Valve ...

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...

Whether transcatheter aortic-valve replacement can improve outcomes in patients with asymptomatic severe aortic stenosis has been unclear. New research findings comparing TAVR with clinical ...

Edwards Lifesciences (NYSE:EW) traded higher on Thursday after Stifel upgraded the heart device maker to Buy from Hold, citing a turnaround in its position in the market for transcatheter aortic valve ...

For these patients, TAVR may be an option. During TAVR, the replacement valve is inserted through a small cut in the thigh into an artery. Doctors use a tube-based delivery system (catheter) to ...

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

Since initial FDA approval in 2011, TAVR has revolutionized ... faculty who come together and review all data to bring about the best outcome in each and every patient,” says Olcay Aksoy ...

With its potential to improve clinical outcomes for a broader range of patients, the JenaValve Trilogy System underscores the growing adaptability of TAVR technology in treating complex heart ...